An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

To determine if baseline/interictal saliva calcitonin gene-related peptide (CGRP) levels would be lower in subjects with chronic migraine receiving onabotulinumtoxinA compared with those receiving saline.

Why It Was Studied

CGRP is considered central to the pathogenesis of episodic migraine, but its relationship to chronic migraine is less understood.

Who Took Part

According to the abstract, 20 subjects were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

This was an exploratory, randomized, placebo-controlled, crossover pilot study of 20 subjects that received onabotulinumtoxinA and saline injection (placebo).

The amount of CGRP in saliva samples collected on a nonheadache or low headache day, and prior to and after treatment of a headache exacerbation was measured.

How the Study Was Run

The design is described as randomized, placebo-controlled, crossover and pilot.

The subjects were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the CGRP (Calcitonin Gene-Related Peptide) group a baseline to be compared against.

In the crossover set-up each of the subjects took both CGRP (Calcitonin Gene-Related Peptide) and the comparison in turn, acting as their own control.

It is described as a pilot, a small early test of whether a larger CGRP (Calcitonin Gene-Related Peptide) study would be practical.

Daily headache records, medications, and response to treatment were recorded in a diary.

What Was Measured

PubMed files the paper under topics including Biomarkers, Botulinum Toxins, Type A, Calcitonin Gene-Related Peptide, Chronic Disease, Migraine Disorders, Pain Measurement and Pilot Projects.

Author keywords: acute treatment, chronic migraine, episodic migraine, onabotulinumtoxinA and pathophysiology.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of CGRP (Calcitonin Gene-Related Peptide) in 20 subjects in people with migraine.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Headache), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.